Litcius/Paper detail

Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial

Aurelio Maggio, Antonis Kattamis, Mariagrazia Felisi, Giorgio Reggiardo, Amal El‐Beshlawy, Mohamed Béjaoui, Laila M. Sherief, Soteroula Christou, Carlo Cosmi, Oscar Della Pasqua, Giancarlo Vecchio, Aldo Filosa, Liana Cuccia, Hoda Hassab, M. Kreka, Raffaella Origa, Maria Caterina Putti, Michael Spino, Paul Telfer, Bianca Tempesta, Angela Vitrano, Yu Chung Tsang, Ariana Zaka, Fernando Tricta, Donato Bonifazi, Adriana Ceci

2020The Lancet Haematology72 citationsDOI

Topics & Concepts

DeferasiroxDeferiproneMedicineDeferoxamineClinical endpointPediatricsRandomized controlled trialAdverse effectThalassemiaInternal medicineClinical trialChelation therapySurgeryHemoglobinopathies and Related DisordersErythropoietin and Anemia TreatmentNeonatal Health and Biochemistry
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial | Litcius